دورية أكاديمية
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
| العنوان: | Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. |
|---|---|
| المؤلفون: | Desai SH; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, USA., Spinner MA; Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA., David K; Department of Hematology and Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA., Bachanova V; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, USA.; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA., Goyal G; O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama, USA., Kahl B; Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, Missouri, USA., Dorritie K; Division of Hematology-Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Azzi J; Division of Hematology and Medical Oncology, Icahn School of Medicine Mount Sinai, New York, New York, USA., Kenkre VP; Department of Hematology, University of Wisconsin, Madison, Wisconsin, USA., Arai S; Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA., Chang C; Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA., Fusco B; Department of Hematology and Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA., Sumransub N; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, USA.; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA., Hatic H; O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama, USA., Saba R; Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, Missouri, USA., Ibrahim U; Division of Hematology and Medical Oncology, Icahn School of Medicine Mount Sinai, New York, New York, USA., Harris EI; Department of Hematology, University of Wisconsin, Madison, Wisconsin, USA., Shah H; Division of Hematology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., Murphy J; Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA., Ansell S; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA., Jagadish D; Cleveland Clinic Foundation, Cleveland, Ohio, USA., Orellana-Noia V; Division of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Diefenbach C; Perlmutter Cancer Center, NYU Grossman Medical School, New York, New York, USA., Iyenger S; Division of Hematology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., Rappazzo KC; Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA., Mishra R; Cleveland Clinic Foundation, Cleveland, Ohio, USA., Choi Y; Perlmutter Cancer Center, NYU Grossman Medical School, New York, New York, USA., Nowakowski GS; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA., Advani RH; Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, California, USA., Micallef IN; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. |
| المصدر: | American journal of hematology [Am J Hematol] 2023 Mar; Vol. 98 (3), pp. 464-471. Date of Electronic Publication: 2023 Jan 11. |
| نوع المنشور: | Multicenter Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York Ny : Wiley-Blackwell Original Publication: New York, Liss. |
| مواضيع طبية MeSH: | Hodgkin Disease*/drug therapy , Hodgkin Disease*/pathology , Hematopoietic Stem Cell Transplantation*, Humans ; Progression-Free Survival ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Neoplasm Recurrence, Local/drug therapy ; Brentuximab Vedotin/therapeutic use ; Stem Cell Transplantation ; Transplantation, Autologous ; Salvage Therapy |
| مستخلص: | Clinical trials of novel salvage therapies have encouraging outcomes for relapsed/refractory transplant-eligible classic Hodgkin lymphoma (R/R cHL) but comparison with conventional chemotherapy is lacking. Herein, we report the final analysis of a multicenter retrospective cohort of R/R cHL assessing outcomes by type of salvage therapy before autologous stem cell transplant (ASCT). R/R cHL patients who underwent ASCT at 14 institutions across the United States were included. Outcomes were compared among patients receiving conventional chemotherapy, brentuximab vedotin (BV) + chemotherapy, BV alone, and a checkpoint inhibitor (CPI)-based regimens before ASCT. Study endpoints included event-free survival (EFS), progression-free survival (PFS), and overall survival (OS). All endpoints are defined from relapse. Of 936 patients, 728 received conventional chemotherapy, 73 received BV + chemotherapy, 70 received BV alone, and 65 received CPI-based regimens prior to ASCT. When adjusted for time to relapse, pre-ASCT response and use of BV maintenance, patients receiving CPI-based regimens had superior 2-year EFS compared to conventional chemotherapy, BV + chemotherapy, and BV alone (79.7, 49.6, 62.3, and 36.9%, respectively, p < .0001). Among 649 patients transplanted after 1 line of salvage therapy, CPI-based regimens were associated with superior 2-year PFS compared to conventional chemotherapy (98% vs. 68.8%, hazard ratio: 0.1, 95% confidence interval: 0.03-0.5, p < .0001). OS did not differ by pre-ASCT salvage regimen. In this large multicenter retrospective study, CPI-based regimens improved EFS and PFS compared to other salvage regimens independent of pre-ASCT response. These data support earlier sequencing of CPI-based regimens in R/R cHL in the pre-ASCT setting. (© 2023 Wiley Periodicals LLC.) |
| التعليقات: | Erratum in: Am J Hematol. 2023 Nov;98(11):1818. doi: 10.1002/ajh.27103. (PMID: 37732813) |
| References: | Br J Haematol. 2020 May;189(3):e86-e90. (PMID: 32048731) Blood. 2021 Aug 12;138(6):427-438. (PMID: 33827139) Blood Adv. 2021 Mar 23;5(6):1648-1659. (PMID: 33710337) Lancet Oncol. 2019 Feb;20(2):202-215. (PMID: 30658935) J Clin Oncol. 2021 Oct 1;39(28):3109-3117. (PMID: 34170745) Lancet. 2002 Jun 15;359(9323):2065-71. (PMID: 12086759) Blood. 2016 Mar 24;127(12):1531-8. (PMID: 26747247) J Clin Oncol. 2016 Aug 10;34(23):2690-7. (PMID: 27069084) Blood. 2019 Oct 3;134(14):1144-1153. (PMID: 31409671) Lancet. 1993 Apr 24;341(8852):1051-4. (PMID: 8096958) J Clin Oncol. 2018 May 10;36(14):1428-1439. (PMID: 29584546) Ann Oncol. 2002 Oct;13(10):1628-35. (PMID: 12377653) Oncologist. 2020 Oct;25(10):878-885. (PMID: 32720734) Blood. 2022 Jun 23;139(25):3605-3616. (PMID: 35316328) Br J Haematol. 2020 Feb;188(4):540-549. (PMID: 31588564) Lancet Oncol. 2015 Mar;16(3):284-92. (PMID: 25683846) Lancet. 2015 May 9;385(9980):1853-62. (PMID: 25796459) J Clin Oncol. 2014 Sep 20;32(27):3059-68. (PMID: 25113753) Blood. 2010 Dec 2;116(23):4934-7. (PMID: 20733154) Blood. 2001 Feb 1;97(3):616-23. (PMID: 11157476) Ann Oncol. 1999 May;10(5):593-5. (PMID: 10416011) J Clin Oncol. 2007 Feb 10;25(5):579-86. (PMID: 17242396) Lancet Oncol. 2021 Apr;22(4):512-524. (PMID: 33721562) Br J Haematol. 2016 Nov;175(3):440-447. (PMID: 27377168) J Clin Oncol. 2017 Jun 20;35(18):1999-2007. (PMID: 28418763) J Clin Oncol. 2016 Sep 20;34(27):3293-9. (PMID: 27382096) N Engl J Med. 2022 Jul 28;387(4):310-320. (PMID: 35830649) |
| معلومات مُعتمدة: | P30 CA047904 United States CA NCI NIH HHS |
| المشرفين على المادة: | 7XL5ISS668 (Brentuximab Vedotin) |
| تواريخ الأحداث: | Date Created: 20230111 Date Completed: 20230216 Latest Revision: 20240711 |
| رمز التحديث: | 20240711 |
| مُعرف محوري في PubMed: | PMC11234511 |
| DOI: | 10.1002/ajh.26827 |
| PMID: | 36629030 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!